Skip to content

AACR Annual Meeting 2026

April 17–22, 2026 · San Diego · 2418 items

← PD-1 × VEGF bispecifics after ivonescimab

VEGF

Clinical trial

2 people · 3 posts · 2 abstracts

A bispecific has three pharmacological edges over a two-drug combo: higher local concentration in the tumor; VEGF is itself an immune suppressor, so blocking it also frees dendritic cells and T-cell entry; vessel normalization lets T cells in.

Most molecules hit PD-1 × VEGF; BioNTech’s BNT327 / pumitamig hits PD-L1 × VEGF-A.

Other cases in this chapter
  • ivonescimabmPFS 11.14 vs 5.82 mo, HR 0.51
  • JS207 + XELOXEarly signal in 1L MSS/pMMR CRC
  • MK-2010First-in-human data, all from China trials
  • pumitamigMulti-indication; TNBC sits under breast
Evidence
Floor
Apr 21Tue
Apr 18Sat
CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org